Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Nkarta, Inc.

35 indications, side-by-side phase, drug & LoA

$2.86

+0.1 (+3.62%)

C 49Pipeline Score Undervalued Biotech · Commercial
Market Cap
216.78 M
EPS
-1.35
P/E Ratio
-
Value Trade
1.31 M
SEC Financials
Q1 2026

  • Dilution Risk

    15%

  • R&D Expenses

    24.99 M

  • Operating CF

    -28.20 M

  • Total Assets

    372.07 M

  • Total Liabilities

    86.21 M

  • Equity

    285.86 M

  • D/E Ratio

    12,345

7.45 %
Week
-10.62 %
1 Month
30.04 %
3 Month
76.16 %
6 Month
-89.09 %
5 Year
-94.47 %
All Time
Cash Data
Stable

  • Cash Position

    230.43 M

  • Monthly Burn

    9.40 M

  • Runway

    23.5 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 12, 2026
Overview
Volume
677.58 K
52 Week Range
1.63 - 3.65
% held by Insiders
24.1 %
% held by Institutions
62.05 %
Enterprise Value
61.35 M
Total Shares
71.02 M
Short %
9.63 %
Float Shares
43.75 M
Company Description
HQ: 1150 VETERANS BOULEVARD, SOUTH...
Employees:108
https://www.nkartatx.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 1 data readout example
NKX019 Multiple autoimmune indications
Phase 1
—
-
-
NKX019 Multiple autoimmune indications
Phase 1
—
-
-
NKX019 Multiple autoimmune indications
Phase 1
—
-
-
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C49
Pipeline Score
$1.4B
Pipeline Value
Undervalued
Valuation Signal
2
Drugs Scored
15.0x
rNPV / MCap
Top 70%
Micro Cap
(rank 272 of 905)
Percentile Rank
Nkarta, Inc. carries a moderate pipeline score (49/100), with $15.6B risk-adjusted pipeline value, led by NKX101 - CAR NK cell therapy in Relapsed/Refractory AML (Phase 1).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
NKX101 - CAR NK cell therapy
Monoclonal antibody		Relapsed/Refractory AMLPhase 1NCT0462394478% $15.0B ACTIVE NOT_RECRUITING 61 SLOW D (32) Jul 1, 2039MODERATE_RISKLOW
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in NKTX
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
NKTX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
NKTX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
NKTX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
NKTX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
NKTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-06-18 0.00 0 - - - - - -
2026-06-18 0.00 0 - - - - - -
2026-06-18 0.00 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Nkarta, Inc. (NKTX) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How NKTX ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Membranous Nephropathy #7 of 7 PHASE 1 NKX019 + Fludarabine, Cyclophosphamide
BIIB NVS ONC
$0.39B 0.76 FOLLOWER
Vasculitis #9 of 16 PHASE 1 NKX019 + Fludarabine + Cyclophosphamide
AZN GSK ABBV
$2.5B 0.82 FOLLOWER
Systemic Sclerosis #15 of 21 PHASE 1 NKX019 + Fludarabine + Cyclophosphamide
AZN BMY MRK
$2.68B 0.82 FOLLOWER
Lupus Nephritis #15 of 17 PHASE 1 NKX019 + Fludarabine, Cyclophosphamide
NVS VTRS AZN
$1.2B 0.76 FOLLOWER
Myelodysplastic Syndromes #23 of 33 PHASE 1 NKX101 - CAR NK cell therapy
BMY ABBV TAK
$2.5B 0.9 FOLLOWER
Leukemia #38 of 64 PHASE 1 NKX101 - CAR NK cell therapy
AMGN LLY AZN
$4.28B 0.83 FOLLOWER
Lymphoma #54 of 69 PHASE 1 NKX019
REGN LLY MRK
$8.52B 0.76 FOLLOWER